Caroline Loew - Dec 14, 2023 Form 4/A Insider Report for Mural Oncology plc (MURA)

Role
Chief Executive Officer, Director
Signature
/s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew
Stock symbol
MURA
Transactions as of
Dec 14, 2023
Transactions value $
$0
Form type
4/A
Date filed
4/11/2024, 09:10 PM
Date Of Original Report
Dec 18, 2023
Previous filing
Nov 7, 2023
Next filing
Mar 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MURA Stock Option (right to buy) Award +380K 380K Dec 14, 2023 Ordinary Shares 380K $5.48 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment to Form 4 is being filed solely to correct the exercise price of the granted option, which was previously reported as being $3.61 due to a scrivener's error.
F2 Represents an option award originally granted by Alkermes plc ("Alkermes") that was converted into an option award of Mural Oncology plc (the "Issuer") in connection with the spin-off of the Issuer from Alkermes.
F3 This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 5, 2023, subject to the reporting person's continued service with the Issuer.